Showing 6381-6390 of 10173 results for "".
- Eirion Therapeutics Closes $40M Series A Investment and Licensing Deal with Shanghai Haohai Biological Technologyhttps://practicaldermatology.com/news/eirion-therapeutics-closes-40m-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology/2460712/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Robert Moccia Takes the Helm at STRATA Skin Scienceshttps://practicaldermatology.com/news/robert-moccia-takes-the-helm-at-strata-skin-sciences/2460705/Robert (Bob) Moccia is the new President and Chief Executive Officer and a member of the board of STRATA Skin Sciences, Inc. He replaces Dolev Rafaeli, PhD, who stepped down last month. “I am confident that STRATA has the technology
- ASDSA, Northwestern University Introduce Cutaneous Procedures Adverse Events Reporting (CAPER) Systemhttps://practicaldermatology.com/news/asds-northwestern-university-introduce-cutaneous-procedures-adverse-events-reporting-caper-system/2460701/The American Society for Dermatologic Surgery Association (ASDSA) and the Northwestern University Department of Dermatology are launching the Cutaneous Procedures Adverse Events Reporting (CAPER) system. This voluntary reporting system gathers patients’ adverse events (AEs) encoun
- With sNDA, Amgen Seeks Approval for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/with-snda-amgen-seeks-approval-for-otezla-in-mild-to-moderate-pso/2460700/Amgen has submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The sNDA is based on data from the Phase 3 ADVANCE trial tha
- Label Update: Simponi Aria Improves Fatigue in PsA, RAhttps://practicaldermatology.com/news/label-update-simponi-aria-improves-fatigue-in-psa-ra/2460699/Simponi Aria (golimumab) from Janssen Pharmaceutical Company of Johnson & Johnson is the first and only fully human anti-tumor necrosis factor (TNF) biologic approved by the FDA to include language in its product label stating that the treatment results in improvement in fatigue for adul
- AbbVie, Evolus Agree to Settlementhttps://practicaldermatology.com/news/abbvie-evolus-agree-to-settlement/2460697/AbbVie, Evolus, and Medytox have agreed to a new settlement to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be
- Researchers Identify Mechanisms That Are Essential for Proper Skin Developmenthttps://practicaldermatology.com/news/researchers-identify-mechanisms-that-are-essential-for-proper-skin-development/2460696/Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development. This discovery could improve develop
- Registration Open for Biologic & Small Molecule NP/PA CME Virtual Bootcamphttps://practicaldermatology.com/news/registration-open-for-biologic-small-molecule-nppa-cme-virtual-bootcamp/2460689/The Biologic & Small Molecule NP/PA CME Virtual Bootcamp is coming Saturday, March 6. Topics for the program, presented by the Dermatology Education Foundation, include therapeutic updates in atopic dermatitis and psoriasis, patient initiation for biologics and small molec
- Potential Psoriasis Breakthrough: Bimekizumab Performs Well in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/potential-psoriasis-breakthrough-bimekizumab-performs-well-in-moderate-to-severe-plaque-psoriasis/2460684/Two new Phase 3 studies show that bimekizumab-treated psoriasis patients achieved superior levels of skin clearance compared to those who received placebo or ustekinumab. The safety profile of bimekizumab was consistent with earlier clinical studies with no new safety signals identified
- Ortho Dermatologics Opens Applications for 2021 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-applications-for-2021-aspire-higher-scholarship-program/2460683/Ortho Dermatologics opened the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals. &ldquo